Europe Liver Disease Treatment Market Research Report – Segmented By Treatment Modality, Disease Type and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Size, Share, Trends and Growth Forecast (2025 to 2033)
The Europe Liver Disease Treatment Market Size was valued at USD 2.59 billion in 2024. The Europe Liver Disease Treatment Market Size is expected to have 11.56% CAGR from 2025 to 2033 and be worth USD 6.93 billion by 2033 from USD 2.89 billion in 2025.
The percentage of the aged population diagnosing with liver-related diseases is significantly increasing in Europe and is primarily driving the growth of the European liver disease treatment market. Europe is among one of the leading markets for Liver Disease Treatment Drugs. As per a report, liver cirrhosis causes 170,000 deaths in Europe annually. Within Europe, Germany, France, and the United Kingdom account for the largest liver disease treatment market share.
Various technological advancements in the imaging techniques, Y-O-Y increase in the patients diagnosing with the liver diseases further contribute to the growth of the market. The increasing number of mergers and acquisitions that are happening between the companies is predicted to shape the face of the market better during the forecast period. The license expiration of a few drugs and robust pipeline drugs for the treatment of liver diseases is adding fuel to the market.
Strict regulations of the FDA, MHRA in approving the new drugs, and high costs required for the development of new drugs, and the high costs associated with the treatment for liver diseases are expected to hamper the market growth to a specific limit.
Geographically, the European liver disease treatment market stands second, following North America in leading the global liver disease treatment market. It is due to viral hepatitis, genetic disorders, unhealthy diet, and excessive intake of alcohol.
Germany, UK, and France account for significant shares of the liver disease treatment market in the region. The growing number of liver disease cases because of the vast drinking population in Europe and increasing obesity and growing new clinical needs in liver diseases are likely to accelerate market growth. The Germany market is rising due to factors like excess intake of over-the-counter high dosage drugs, reimbursement policies for liver diseases in the healthcare sector, government, and other private organizations bring out the awareness by organizing programs regarding liver disease treatment which propels the market during the analysis period. Alcohol consumption is considered to cause 20%-50%of cirrhosis of the liver, and around 13% of the population across the globe, i.e., more than 600 million adults, are obese according to World Health Organization. Moreover, Cirrhosis can cause 170,000 deaths in Europe every year.
Companies playing a vital role in the European Liver Disease Treatment Market profiled in the report are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany) and AstraZeneca (United Kingdom).
By Treatment Modality
By Disease Type
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region